• FirefoxInstall the new Firefox »
  •  Dow Up1.39% Nasdaq Up0.68%

    More On SHP.L

    Quotes

    Charts

    News & Info

    Company

    Analyst Coverage

    Ownership

    • Major Holders
    • Insider Transactions
    • Insider Roster

    Financials


    Shire plc (SHP.L)

    -LSE
    5,410.00 Down 15.00(0.28%) 10:20AM EDT
    Add to Portfolio
    ProfileGet Profile for:
    Shire plc
    5 Riverwalk
    Citywest Business Campus
    Dublin, 24
    Ireland - Map
    Phone: 353 1 429 7700
    Website: http://www.shire.com

    Details 
    Index Membership:N/A
    Sector:Healthcare
    Industry:Biotechnology
    Full Time Employees:5,016

    Business Summary 

    Shire plc, a biopharmaceutical company, together with its subsidiaries, researches, develops, licenses, manufactures, markets, distributes, and sells pharmaceutical products. It offers various products for the treatment of attention deficit hyperactivity disorder (ADHD), including VYVANSE/ VENVANSE/ ELVANSE/ TYVENSE/ ELVANS E VUXEN/ADUVANZ; INTUNIV, an alpha-2A receptor agonist; EQUASYM, a methylphenidate hydrochloride; and ADDERALL XR, an extended release treatment for ADHD. The company also provides BUCCOLAM for epilepsy treatment; PENTASA and LIALDA/MEZAVANT for ulcerative colitis treatment; and RESOLOR, a 5-HT4 receptor agonist that is used for the treatment of chronic constipation in women. In addition, it offers REPLAGAL for the treatment of Fabry disease; ELAPRASE for the treatment of hunter syndrome; VPRIV for the treatment of type 1 Gaucher disease; and FIRAZYR and CINRYZE C1 esterase inhibitor for the treatment of hereditary angioedema. Further, the company provides FOSRENOL, a phosphate binder for use in end-stage renal disease receiving dialysis; XAGRID that is used for the reduction of elevated platelet counts in at-risk essential thrombocythemia patients; and PLENADREN for the treatment of adrenal insufficiency. Additionally, it licenses its patented antiviral products for human immunodeficiency virus and hepatitis B virus. The company also focuses on the development of resources projects in various therapeutic areas, including rare diseases, neuroscience, ophthalmics, hematology, and gastrointestinal disorders; and early development projects primarily on rare diseases. Shire plc markets its products through wholesalers and pharmacies. The company has research collaboration with ArmaGen Technologies Inc., Santaris Pharma A/S, and Sangamo. Shire plc was founded in 1986 and is based in Dublin, Ireland.

    Key Statistics


    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Shire plc

    Key Executives 
     PayExercised
    Dr. Flemming Ornskov M.D., MBA, MPH, 57
    Chief Exec. Officer, Managing Director and Director
    4.14MN/A
    Mr. Jeffrey Poulton , 47
    Interim Chief Financial Officer
    N/AN/A
    Ms. Marianne Jackson ,
    Head of Global Commercial Operations
    N/AN/A
    Mr. William Ciambrone ,
    Head of Technical Operations
    N/AN/A
    Mr. Mark J. Enyedy , 51
    Head of Corp. Devel. and Interim Gen. Counsel
    N/AN/A
    Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in GBp.